ctDNA levels predict clinical outcomes of targeted therapy for advanced melanoma

Analysis of blood samples of patients in the COMBI-d and COMBI-MB trials showed that pretreatment and on-treatment BRAF^V600-mutant ctDNA levels could serve as independent, predictive biomarkers of clinical outcome with targeted therapy for advanced melanoma.